Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5944822 | 0.77 | KDM4E (0.35) | L3MBTL1LMNAHTTKDM4EUSP2 | |
| SCHEMBL4146608 | 0.73 | PCTP (0.37) | L3MBTL1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL4146606 | 0.73 | PCTP (0.37) | L3MBTL1LMNAKDM4EALDH1A1POLB | |
| SCHEMBL5894852 | 0.72 | IDO1 (0.34) | HTTUSP2ALDH1A1MAPTHPGD | |
| SCHEMBL5894803 | 0.72 | IDO1 (0.38) | HTTUSP2MAPTHTR6KMT2A | |
| SCHEMBL11314107 | 0.71 | — | — | |
| SCHEMBL4639026 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL11705113 | 0.70 | CYP3A4 (0.41) | L3MBTL1LMNAHTTTDP1KMT2A | |
| SCHEMBL11458541 | 0.67 | — | — | |
| SCHEMBL15528571 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385042-B1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-25 | — | — | EP | disclosed |
| EP-1973886-B1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-27 | — | — | EP | disclosed |
| EP-2385042-A1 | Prokineticin 1 receptor antagonists | Janssen Pharmaceutica N.V. (BE) | 2011-11-09 | — | — | EP | disclosed |
| US-8039028-B2 | Use of an extract of the orchid Vanda coerulea as a skin hydrating agent | LVMH REACHERCHE (FR) | 2011-10-18 | — | — | US | disclosed |
| US-7939537-B2 | HIV integrase inhibitors | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2011-05-10 | — | — | US | disclosed |
| US-20090221571-A1 | HIV INTEGRASE INHIBITORS | MSD ITALIA S.R.L. (IT) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221571-A1 | HIV INTEGRASE INHIBITORS | TYMP, CDK2, TYMS | L3MBTL1 1350/4885LMNA 3511/4885HTT 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.